Ging-Jehli, Nadja Rita http://orcid.org/0000-0002-1071-0693
Manda, Deepa
Hollway, Jill http://orcid.org/0000-0001-6796-1947
Hurt, Elizabeth
Moone, Stacey
Arnold, L. Eugene http://orcid.org/0000-0002-0886-0692
Funding for this research was provided by:
Autism Speaks (8UL18TR000090-05)
Article History
Accepted: 20 October 2020
First Online: 3 November 2020
Compliance with Ethical Standards
:
: Nadja Ging-Jehli, Deepa Manda, Elizabeth Hurt, and Stacey Moone have no conflicts of interest to disclose. Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. Dr. Hollway has received research contracts, or research support from Forest Research Institute, Sunovion Pharmaceuticals, F. Hoffman-La Roche, Supernus, Young Living, Autism Speaks, and the NIH. She has served on the advisory board for YAMO Pharmaceuticals and has consulted with MedAvante-ProPhase.
: The research was approved by The Ohio State University’s Institutional Review Board (IRB). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Written informed consent and assent (if the child was capable) was obtained from parents. The authors affirm that human research participants provided informed consent for the use and share of their de-identified information for future research and publication.
: Informed consent from parents and assent (if the child was capable) from participants was obtained using forms and procedures approved by the Ohio State University IRB.
: The authors affirm that human research participants provided informed consent for the use and share of their de-identified information for future research and publication.